ContraFect Management
Management criteria checks 3/4
ContraFect's CEO is Mike Messinger, appointed in Nov 2018, has a tenure of 5.08 years. total yearly compensation is $957.21K, comprised of 42.9% salary and 57.1% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $1.42. The average tenure of the management team and the board of directors is 2.5 years and 9.7 years respectively.
Key information
Mike Messinger
Chief executive officer
US$957.2k
Total compensation
| CEO salary percentage | 42.9% |
| CEO tenure | 5.1yrs |
| CEO ownership | 0.0002% |
| Management average tenure | 2.5yrs |
| Board average tenure | 9.7yrs |
Recent management updates
Recent updates
Contrafect GAAP EPS of -$0.46 misses by $0.13
Aug 15ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial
Jul 13ContraFect (NASDAQ:CFRX) Is In A Good Position To Deliver On Growth Plans
Jun 29
Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?
Dec 25ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market
Sep 15We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate
Aug 18Is ContraFect (NASDAQ:CFRX) In A Good Position To Deliver On Growth Plans?
May 01Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?
Mar 09Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?
Jan 15What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?
Nov 24Contrafect EPS beats by $0.16
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | n/a | n/a | -US$36m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | US$957k | US$410k | -US$65m |
| Sep 30 2022 | n/a | n/a | -US$60m |
| Jun 30 2022 | n/a | n/a | -US$48m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$883k | US$389k | -US$20m |
| Sep 30 2021 | n/a | n/a | -US$22m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$1m | US$374k | -US$28m |
| Sep 30 2020 | n/a | n/a | -US$32m |
| Jun 30 2020 | n/a | n/a | -US$41m |
| Mar 31 2020 | n/a | n/a | -US$32m |
| Dec 31 2019 | n/a | n/a | -US$13m |
| Sep 30 2019 | n/a | n/a | US$3m |
| Jun 30 2019 | n/a | n/a | US$4m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | n/a | n/a | -US$38m |
| Sep 30 2018 | n/a | n/a | -US$48m |
| Jun 30 2018 | n/a | n/a | -US$46m |
| Mar 31 2018 | n/a | n/a | -US$28m |
| Dec 31 2017 | US$616k | US$315k | -US$16m |
Compensation vs Market: Mike's total compensation ($USD957.21K) is about average for companies of similar size in the US market ($USD740.57K).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
CEO
Mike Messinger (48 yo)
5.1yrs
Tenure
US$957,211
Compensation
Mr. Michael Messinger, C.P.A., also known as Mike, is President and Chief Executive Officer at ContraFect Corporation since November 15, 2023. He has been Chief Financial Officer of ContraFect Corp. since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 5.1yrs | US$957.21k | 0.00021% $ 1.4 | |
| General Counsel | 9.3yrs | US$844.90k | 0.000010% $ 0.07 | |
| Vice President of Human Resources | 1.8yrs | no data | no data | |
| Senior Vice President of Translational Sciences & Preclinical Development | 2.5yrs | no data | no data | |
| Interim Chief Medical Officer | 1.3yrs | no data | no data |
2.5yrs
Average Tenure
54yo
Average Age
Experienced Management: CFRX's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Lead Independent Director | 12.7yrs | US$176.04k | 0.0095% $ 64.4 | |
| Vice Chairman | 8.6yrs | US$160.54k | 0.00024% $ 1.6 | |
| Independent Director | 3.5yrs | US$150.54k | 0% $ 0 | |
| Chairman | 9.7yrs | US$2.23m | 0.000010% $ 0.07 | |
| Independent Director | 9.7yrs | US$160.04k | 0.000090% $ 0.6 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 13.6yrs | US$155.54k | 0.00072% $ 4.9 | |
| Independent Director | 9.7yrs | US$165.04k | 0.0043% $ 29.3 | |
| Member of Scientific Advisory Board | no data | no data | no data |
9.7yrs
Average Tenure
70yo
Average Age
Experienced Board: CFRX's board of directors are considered experienced (9.7 years average tenure).